ClinicalTrials.gg
RecruitingNCT06167369Updated Feb 20, 2024

Biological and Cognitive Marker of Neurodegeneration in Obstructive Sleep Apnea Patients

An observational study in Sleep Apnea, Obstructive, sponsored by Technische Universität Dresden. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Technische Universität Dresden · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
136
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Sleep Apnea, Obstructive with a site in Germany — 7 open to participants now, 13 under way, 5 of them phase 3. Sleep Apnea, Obstructive · Germany.

Planned enrollment
7th of 13
136 · median 136
Started
2024
with 2 others
Observational
13 of 68
3 open now
Primary completion
2025-12
later than 2 of 12 live
Registered
59th of 68
by date

Among the 68 studies in Sleep Apnea, Obstructive with a site in Germany, this one is the 7th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 59th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

7 of the 68 studies in Sleep Apnea, Obstructive with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Sleep Apnea, Obstructive with a site in Germany, or all of them as a file.
02

Study summary

The goal of this observational study is to investigate biomarkers and neurocognitive markers of neurodegenerative processes in obstructive sleep apnea patients.

The main questions the study aims to answer are:

  • Does neurodegeneration assessed by neurobiological markers and neurocognitive test performance exists in obstructive sleep apnea?
  • Are these neurodegenerative markers are associated with the adherence to clinical prescribed positive airway pressure therapy?

Newly diagnosed patients with obstructive sleep apnea will be observed during the use of clinical prescribed positive pressure therapy. Different study related investigations take place before and six months after treatment start.

Researchers will compare after six months the group of adherent treatment participants with the non-adherent treatment participants group to investigate if differences in the observed neurobiological or neurocognitive parameters exist.

03

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • Sleep apnea
  • Neurodegeneration
  • Neurofilament light chain
  • Glial fibrillary acidic protein
  • Positive airway pressure therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients that are reffered to the sleep lab of the University Hospital Dresden

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • newly diagnosed obstructive sleep apnea
  • clinical indication for start of positive airwas pressure therapy
  • Age older than 18 years

Exclusion criteria

Exclusion Criteria:

  • neurodegenerative disease
  • Multiple sclerosis
  • Stroke within last 3 months
  • Brain injury within last 3 months
  • \< 21 points
  • higher degree chonic kidney disease (lower than 30 mL/min)
  • regular use of sleep pills (e.g. Zopiclon, Mirtazapin, Daridorexant)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
136 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Newly diagnosed sleep apnea patients, starting clinical prescribed positive airway pressure therapy
06

What researchers measure

Primary outcomes

  1. Concentration of neurofilament light chain

    longitudinal analysis

    Time frame: From enrollment to the follow up time point after 6 months of treatment

Secondary outcomes

  1. Concentration of Neurofilament light chain

    in between the groups (assessed after 6 months)

    Time frame: From enrollment to the follow up time point after 6 months of treatment, in between the groups

  2. Concentration of Glial fibrillary acidic protein

    longitudinal analysis and in between the groups (assessed after 6 months)

    Time frame: From enrollment to the follow up time point after 6 months of treatment

  3. Cognitive performance measured by SDMT, MoCA

    Longitudinal analysis and in between the groups (assessed after 6 months)

    Time frame: From enrollment to the follow up time point after 6 months of treatment

  4. Objective sleep parameters measured by polysomnography or equivalent measuremt methods

    Longitudinal analysis and in between the groups (assessed after 6 months). For example objective parameters like apnea-hypopnea-index per hour or sleep efficacy in %.

    Time frame: From enrollment to the follow up time point after 6 months of treatment

  5. Subjective sleep parameters measured by symptoms questionnaires (Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index)

    Longitudinal analysis and in between the groups (assessed after 6 months). For example parameters like sleepiness (ESS-questionnnaire, min to max 0 to 24 points) or sleep quality (PSQI-questionnaire, min to max 0 to 21 points). Lower score values represent fewer symptom load.

    Time frame: From enrollment to the follow up time point after 6 months of treatment

07

Study locations

1 of 1 sites recruiting
  • Technische Universität Dresden, Universitätsklinikum Dresden
    Dresden, Saxony 01307, Germany
    Recruiting
    • Tony Sehr, MD · Contacttony.sehr@ukdd.de · +49 351 458 0
    • Tony Sehr, MD · Principal investigator
    • Moritz D Brandt, MD · Principal investigator
    • Tjalf Ziemssen, MD · Sub investigator
    • Katja Akgün, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
Dec 12, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 2026
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06167369
Responsible party
Tony Sehr (Principal Investigator, Technische Universität Dresden) — Principal investigator
First posted
Dec 12, 2023
Start date
Jan 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Feb 20, 2024

Study contacts

Tony Sehr, MD
Contact
tony.sehr@ukdd.de
+49 351 458 19324
Moritz D Brandt, MD
Contact
moritz.brandt@ukdd.de

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion